Onco Actu du 30 mars 2018

	1. Biologie
‘Newfound’ organ = old school hype. What you need to know [HealthNewsReview] I’ve spoken with other doctors about this study, all of whom were exasperated by the marketing of this ‘new organ’ in what’s otherwise a good study.” As for this technology “explaining how cancer spreads” or being an “aid in cancer diagnosis” that is speculative at this point.
Scientists find mini gastrointestinal tract growing inside tumor [STAT] Duke University researchers have observed rudimentary, but functional, stomachs, small intestines, and duodenums growing inside cancerous lungs — illustrating how varied and plastic these metastatic cells can be.
	3.8 Prévention - Alimentation
Coffee must carry cancer warning, California judge rules [Washington Post] In addition to the warning signs likely to result from the lawsuit, the Council for Education and Research on Toxics, which brought the lawsuit, has asked for fines as much as $2,500 for every person exposed to the chemical since 2002, potentially opening the door to massive settlements.
California judge rules Starbucks coffee must come with cancer warning [The Guardian] A Los Angeles judge has ruled that California law requires coffee companies to carry an ominous cancer warning label because of a chemical produced in the roasting process.
	4.12 Biopsies liquides
Institut Curie to Evaluate Freenome AI Platform for Analyzing cfDNA in Cancer Patients [Genome Web] Researchers will use Freenome's Adaptive Genomics Engine technology, which combines genome-wide sequencing and machine learning, to analyze patterns in cell-free DNA.
Insufficient Evidence of Clinical Validity and Utility for the Majority of ctDNA Assays in Advanced Cancer [ESMO] Robust research is needed in several areas to enable development of clinical practice recommendations.
	4.2 Dép., diag. & prono. - Génome
Clinical Sequencing Promises Diagnosis, Treatment Clues But Reality Often Falls Short [Genome Web] Several speakers at the 2018 Genomic Medicine Conference held here by the HudsonAlpha Institute for Biotechnology recounted cases that showcased the impact sequencing-based testing has had on their clinical practice.
	5.12.8 Immunothérapies - Economie
Unum IPO hits bottom of range, netting $62M for cell therapy cancer trials [FierceBiotech] Unum plans to spend about $20 million to finish a phase 1 trial of its lead antibody-coupled T cell receptor, ACTR087, in combination with rituximab in adults with relapsed or refractory B cell non-Hodgkin lymphoma (NHL) That is the trial in which two patients died from drug-related adverse events and a third died after suffering a severe case of cytokine release syndrome linked to ACTR087.
	5.2 Pharma
Tiny Redx slammed after first patient is hit by adverse events, forcing a halt to cancer drug study [EndPoints] The UK biotech has suspended a Phase I/II trial after the first patient dosed experienced serious adverse events that were “possibly related to RXC004 on-target effects and Wnt pathway inhibition.
	5.2.2 Pharma - Fusions & Acquisitions
Takeda shares plummeted on Shire deal buzz. Is a buyout now out of reach? [FiercePharma] “Takeda is just desperate to beef up its pipeline, and they’ve been doing small bits of acquisitions on the biotech side. But how are they going to finance $40 billion?”
	5.2.3 Pharma - économie
AbbVie Has a Growing Credibility Problem [Bloomberg] It keeps over-promising, despite evidence biotech investors hate under-delivery.
	5.3.4 Traitements - AMM (FDA, EMA,...)
FDA Approves BLINCYTO® (blinatumomab) To Treat Minimal Residual Disease-Positive B-Cell Precursor Acute Lymphoblastic Leukemia In Adults And Children [Amgen] BLINCYTO is a bispecific CD19-directed CD3 T cell engager (BiTE®) immunotherapy that binds to CD19 expressed on the surface of cells of B-lineage origin and CD3 expressed on the surface of T cells.
FDA expands approval of Blincyto for treatment of a type of leukemia in patients who have a certain risk factor for relapse [FDA] The efficacy of Blincyto in MRD-positive ALL was shown in a single-arm clinical trial that included 86 patients in first or second complete remission who had detectable MRD in at least 1 out of 1,000 cells in their bone marrow.
FDA expands use of Amgen leukemia drug Blincyto to patients with relapse risk [Reuters] Amgen’s sales of Blincyto, which has an average wholesale price near $173,000, totaled $175 million last year.
	5.5 ASCO
Precision Medicine: A Conversation with Dr. Bruce E. Johnson [ASCO] Things can be actionable—and one of the things that they consider actionable is referral for a clinical trial—but what you really want to know about is the agent against that particular driver. Is there enough information that you could say that the person is likely to benefit from the therapeutic intervention?
	6.4 Médico-éco
Man's £54,000 NHS cancer bill raises ethical questions that can't be ignored [The Guardian] The Royal Marsden said Albert Thompson’s treatment requires payment. It’s the first step in applying the same logic to us all.
	6.7 DMP, Big Data & applis
The government wants to free your health data. Will that unleash innovation? [STAT] Health data specialists said the U.S. is a long way from creating that kind of capability. Patient information, though more widely available in de-identified form, is still scattered among various parties in formats that are difficult to mine for meaningful insights.
	6.7.2 Applis
Apple's plan to put health records on your phone has huge implications for medicine [CNBC] That's rapid growth, but what matters the most is the mission underlying the software. And that's the revolutionary notion of empowering patients with their own health information.
Apple’s Health app can now display medical records from 39 health systems [The Verge] Now, patients with iPhones can see health information including allergies and lab test results.